MAY 22, 2013
Bausch & Lomb announced FDA approval of its Trulign toric posterior chamber IOL. According to Bausch & Lomb the Truligan is the first toric IOL that can also improve vision across a natural range of focus.
The company says the new IOL, a toric model of Bausch & Lomb's Crystalens (models AT-50SE and AT-52SE), is intended for patients with or without presbyopia who want both a reduction in residual refractive cylinder and increased independence from glasses.
Trulign demonstrated improve uncorrected near, intermediate and distance vision in the FDA trial. The company says the haptic design provided superior rotational stability, with 96.1 percent of the lenses rotating less than five degrees from the day of surgery to six months postop.
"I'm very excited about the Trulign IOL because it is the first product that addresses two important unmet clinical needs of cataract patients in a single procedure: One of which is offsetting substantial preexisting corneal astigmatism, which impacts over one in three patients. The other is the desire that patients express to have excellent uncorrected distance and intermediate vision with improved near vision," said Dr. Jay Pepose, who served as medical monitor of the FDA trial.